Lashinger, Laura M <br/><br/>
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.  [electronic resource] 

 -  Cancer research  Jun 2005 
 - 4902-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-04-3701  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Apoptosis Regulatory Proteins<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Caspase 3<br/>Caspase 8<br/>Caspases--metabolism<br/>Cell Cycle Proteins--metabolism<br/>Cell Line, Tumor<br/>Cyclin-Dependent Kinase Inhibitor p21<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Enzyme Activation--drug effects<br/>Humans<br/>Male<br/>Membrane Glycoproteins--pharmacology<br/>Prostatic Neoplasms--drug therapy<br/>Pyrazines--pharmacology<br/>TNF-Related Apoptosis-Inducing Ligand<br/>Tumor Necrosis Factor-alpha--pharmacology<br/>Urinary Bladder Neoplasms--drug therapy